TAAR1 Agonism: An Emerging Target in Schizophrenia Management
TAAR1 Agonism: An Emerging Target in Schizophrenia Management is organized by Integrity Continuing Education Inc.
Program Overview:
Although there are many treatment options for patients with schizophrenia, for more than 70 years there has been only one therapeutic approach: dopamine blockade at the post-synaptic receptor. All currently available antipsychotics work through this mechanism of action. While this is often effective for reducing the positive symptoms of schizophrenia, it typically does little to manage negative symptoms or cognitive deficits, and discontinuation rates are often high due to adverse effects such as weight gain and involuntary movement disorders.
Recent insights into other neural networks involved in the pathophysiology of schizophrenia have led to the development of novel treatments that would target different neurotransmitters, potentially improving other symptom domains while reducing the risk for metabolic and neurologic adverse effects. One of the most promising of these is agonism of the trace amine-associated receptor 1 (TAAR1), which resides intracellularly in both the pre- and post-synaptic neuron.
Learning Objectives:
Upon completion of this educational activity, participants should be able to:
• Improve clinician knowledge about current treatments for schizophrenia and gaps in management
• Describe the mechanism of action and clinical rationale for TAAR1 agonism in the treatment of schizophrenia
• Review available safety and efficacy data for emerging TAAR1 agonists under development for schizophrenia.